pimozide
E567198
diphenylbutylpiperidine derivative
dopamine receptor antagonist
small molecule
typical antipsychotic drug
Pimozide is a typical antipsychotic medication primarily used to treat Tourette’s disorder and severe tics.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
diphenylbutylpiperidine derivative
ⓘ
dopamine receptor antagonist ⓘ small molecule ⓘ typical antipsychotic drug ⓘ |
| actsOn |
dopamine D2 receptor
ⓘ
dopamine D3 receptor ⓘ dopamine D4 receptor ⓘ |
| crossesBloodBrainBarrier | true ⓘ |
| hasAdverseEffect |
QT prolongation
ⓘ
akathisia ⓘ extrapyramidal symptoms ⓘ hyperprolactinemia ⓘ parkinsonism ⓘ sedation ⓘ tardive dyskinesia ⓘ torsades de pointes (rare) ⓘ weight gain ⓘ |
| hasATCCode | N05AG02 ⓘ |
| hasBlackBoxWarning |
risk of QT interval prolongation
ⓘ
risk of serious ventricular arrhythmias ⓘ |
| hasBrandName | Orap NERFINISHED ⓘ |
| hasCASNumber | 2062-78-4 ⓘ |
| hasChemicalFormula | C28H29F2N3O ⓘ |
| hasContraindication |
concurrent use of CYP3A4 inhibitors that prolong QT interval
ⓘ
congenital long QT syndrome ⓘ history of cardiac arrhythmias ⓘ |
| hasEffect |
reduces frequency and severity of motor tics
ⓘ
reduces vocal tics ⓘ |
| hasHalfLife | approximately 55 to 66 hours ⓘ |
| hasIndication |
chronic psychotic disorders
ⓘ
delusional disorder (off-label in some regions) ⓘ schizophrenia (second-line) ⓘ |
| hasIUPACName | 1-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one ⓘ |
| hasLegalStatus | prescription only (in many countries) ⓘ |
| hasMechanismOfAction | blocks postsynaptic dopamine receptors in the brain ⓘ |
| hasMolarMass | 461.55 g/mol ⓘ |
| hasPharmacologicalClass |
antidopaminergic agent
ⓘ
neuroleptic ⓘ |
| hasPregnancyCategory | C (US, historical classification) ⓘ |
| hasPrimaryIndication |
Tourette syndrome
NERFINISHED
ⓘ
severe tics ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| isAvailableAs | oral tablet ⓘ |
| isHighlyProteinBound | true ⓘ |
| isMetabolizedBy |
CYP1A2
NERFINISHED
ⓘ
CYP2D6 NERFINISHED ⓘ CYP3A4 NERFINISHED ⓘ |
| wasApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.